
No change: table 0 B 1
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value B: Respiratory System
  Third character (Operation) is value 1: Bypass: Altering the route of passage of the contents of a tubular body part

No change: First panel of table 0 B 1
  Fourth character (Body Part) is value 1: Trachea
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value D: Intraluminal Device
  Seventh character (Qualifier) is value 6: Esophagus

No change: Second panel of table 0 B 1
  Fourth character (Body Part) is value 1: Trachea
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) has 2 choices.
    First choice is value F: Tracheostomy Device
    Second choice is value Z: No Device
  Seventh character (Qualifier) is value 4: Cutaneous

No change: Third panel of table 0 B 1
  Fourth character (Body Part) is value 1: Trachea
  Fifth character (Approach) has 2 choices.
    First choice is value 3: Percutaneous
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 2 choices.
    First choice is value F: Tracheostomy Device
    Second choice is value Z: No Device
  Seventh character (Qualifier) is value 4: Cutaneous

FY2025: Fourth panel of table 0 B 1
  Fourth character (Body Part) is value 1: Trachea
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value D: Intraluminal Device
  Seventh character (Qualifier) is value 6: Esophagus

FY2025: table 0 C Y
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value C: Mouth and Throat
  Third character (Operation) is value Y: Transplantation: Putting in or on all or a portion of a living body part taken from another individual or animal to physically take the place and/or function of all or a portion of a similar body part

FY2025: First panel of table 0 C Y
  Fourth character (Body Part) is value S: Larynx
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Allogeneic
    Second choice is value 1: Syngeneic

No change: table 0 D X
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value D: Gastrointestinal System
  Third character (Operation) is value X: Transfer: Moving, without taking out, all or a portion of a body part to another location to take over the function of all or a portion of a body part

No change: First panel of table 0 D X
  Fourth character (Body Part) is value 6: Stomach
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value 5: Esophagus

FY2025: Second panel of table 0 D X
  Fourth character (Body Part) is value 8: Small Intestine
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 6 choices.
    First choice is value 5: Esophagus
    Second choice is value 7: Vagina
    Third choice is value B: Bladder
    Fourth choice is value C: Ureter, Right
    Fifth choice is value D: Ureter, Left
    Sixth choice is value F: Ureters, Bilateral

No change: Third panel of table 0 D X
  Fourth character (Body Part) is value E: Large Intestine
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value 5: Esophagus
    Second choice is value 7: Vagina
    Third choice is value B: Bladder

No change: Fourth panel of table 0 D X
  Fourth character (Body Part) is value U: Omentum
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 4 choices.
    First choice is value V: Thoracic Region
    Second choice is value W: Abdominal Region
    Third choice is value X: Pelvic Region
    Fourth choice is value Y: Inguinal Region

No change: table 0 S G
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value S: Lower Joints
  Third character (Operation) is value G: Fusion: Joining together portions of an articular body part rendering the articular body part immobile

No change: First panel of table 0 S G
  Fourth character (Body Part) has 3 choices.
    First choice is value 0: Lumbar Vertebral Joint
    Second choice is value 1: Lumbar Vertebral Joints, 2 or more
    Third choice is value 3: Lumbosacral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 3 choices.
    First choice is value 7: Autologous Tissue Substitute
    Second choice is value J: Synthetic Substitute
    Third choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) has 3 choices.
    First choice is value 0: Anterior Approach, Anterior Column
    Second choice is value 1: Posterior Approach, Posterior Column
    Third choice is value J: Posterior Approach, Anterior Column

No change: Second panel of table 0 S G
  Fourth character (Body Part) has 3 choices.
    First choice is value 0: Lumbar Vertebral Joint
    Second choice is value 1: Lumbar Vertebral Joints, 2 or more
    Third choice is value 3: Lumbosacral Joint
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value A: Interbody Fusion Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Anterior Approach, Anterior Column
    Second choice is value J: Posterior Approach, Anterior Column

FY2025: Third panel of table 0 S G
  Fourth character (Body Part) has 3 choices.
    First choice is value 5: Sacrococcygeal Joint
    Second choice is value 7: Sacroiliac Joint, Right
    Third choice is value 8: Sacroiliac Joint, Left
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 4 choices.
    First choice is value 4: Internal Fixation Device
    Second choice is value 7: Autologous Tissue Substitute
    Third choice is value J: Synthetic Substitute
    Fourth choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fourth panel of table 0 S G
  Fourth character (Body Part) has 14 choices.
    First choice is value 9: Hip Joint, Right
    Second choice is value B: Hip Joint, Left
    Third choice is value C: Knee Joint, Right
    Fourth choice is value D: Knee Joint, Left
    Fifth choice is value F: Ankle Joint, Right
    Sixth choice is value G: Ankle Joint, Left
    Seventh choice is value H: Tarsal Joint, Right
    Eighth choice is value J: Tarsal Joint, Left
    Ninth choice is value K: Tarsometatarsal Joint, Right
    Tenth choice is value L: Tarsometatarsal Joint, Left
    Eleventh choice is value M: Metatarsal-Phalangeal Joint, Right
    Twelfth choice is value N: Metatarsal-Phalangeal Joint, Left
    Thirteenth choice is value P: Toe Phalangeal Joint, Right
    Fourteenth choice is value Q: Toe Phalangeal Joint, Left
  Fifth character (Approach) has 3 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
  Sixth character (Device) has 6 choices.
    First choice is value 3: Internal Fixation Device, Sustained Compression
    Second choice is value 4: Internal Fixation Device
    Third choice is value 5: External Fixation Device
    Fourth choice is value 7: Autologous Tissue Substitute
    Fifth choice is value J: Synthetic Substitute
    Sixth choice is value K: Nonautologous Tissue Substitute
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 T T
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value T: Urinary System
  Third character (Operation) is value T: Resection: Cutting out or off, without replacement, all of a body part

FY2025: First panel of table 0 T T
  Fourth character (Body Part) has 2 choices.
    First choice is value 0: Kidney, Right
    Second choice is value 1: Kidney, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 4 choices.
    First choice is value 0: Allogeneic
    Second choice is value 1: Syngeneic
    Third choice is value 2: Zooplastic
    Fourth choice is value Z: No Qualifier

FY2025: Second panel of table 0 T T
  Fourth character (Body Part) has 2 choices.
    First choice is value 0: Kidney, Right
    Second choice is value 1: Kidney, Left
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Hand-Assisted
    Second choice is value Z: No Qualifier

FY2025: Third panel of table 0 T T
  Fourth character (Body Part) is value 2: Kidneys, Bilateral
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2025: Fourth panel of table 0 T T
  Fourth character (Body Part) is value 2: Kidneys, Bilateral
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Hand-Assisted
    Second choice is value Z: No Qualifier

No change: Fifth panel of table 0 T T
  Fourth character (Body Part) has 7 choices.
    First choice is value 3: Kidney Pelvis, Right
    Second choice is value 4: Kidney Pelvis, Left
    Third choice is value 6: Ureter, Right
    Fourth choice is value 7: Ureter, Left
    Fifth choice is value B: Bladder
    Sixth choice is value C: Bladder Neck
    Seventh choice is value D: Urethra
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
    Third choice is value 7: Via Natural or Artificial Opening
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 0 U 7
  First character (Section) is value 0: Medical and Surgical
  Second character (Body System) is value U: Female Reproductive System
  Third character (Operation) is value 7: Dilation: Expanding an orifice or the lumen of a tubular body part

FY2025: First panel of table 0 U 7
  Fourth character (Body Part) has 5 choices.
    First choice is value 5: Fallopian Tube, Right
    Second choice is value 6: Fallopian Tube, Left
    Third choice is value 7: Fallopian Tubes, Bilateral
    Fourth choice is value 9: Uterus
    Fifth choice is value G: Vagina
  Fifth character (Approach) has 5 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 7: Via Natural or Artificial Opening
    Fifth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) has 2 choices.
    First choice is value D: Intraluminal Device
    Second choice is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2025: Second panel of table 0 U 7
  Fourth character (Body Part) is value C: Cervix
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) has 2 choices.
    First choice is value D: Intraluminal Device
    Second choice is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

FY2025: Third panel of table 0 U 7
  Fourth character (Body Part) is value C: Cervix
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device) is value D: Intraluminal Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value J: Temporary
    Second choice is value Z: No Qualifier

FY2025: Fourth panel of table 0 U 7
  Fourth character (Body Part) is value C: Cervix
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifth panel of table 0 U 7
  Fourth character (Body Part) is value K: Hymen
  Fifth character (Approach) has 6 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
    Third choice is value 4: Percutaneous Endoscopic
    Fourth choice is value 7: Via Natural or Artificial Opening
    Fifth choice is value 8: Via Natural or Artificial Opening Endoscopic
    Sixth choice is value X: External
  Sixth character (Device) has 2 choices.
    First choice is value D: Intraluminal Device
    Second choice is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 1 0 D
  First character (Section) is value 1: Obstetrics
  Second character (Body System) is value 0: Pregnancy
  Third character (Operation) is value D: Extraction: Pulling or stripping out or off all or a portion of a body part by the use of force

No change: First panel of table 1 0 D
  Fourth character (Body Part) is value 0: Products of Conception
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 3 choices.
    First choice is value 0: High
    Second choice is value 1: Low
    Third choice is value 2: Extraperitoneal

No change: Second panel of table 1 0 D
  Fourth character (Body Part) is value 0: Products of Conception
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 6 choices.
    First choice is value 3: Low Forceps
    Second choice is value 4: Mid Forceps
    Third choice is value 5: High Forceps
    Fourth choice is value 6: Vacuum
    Fifth choice is value 7: Internal Version
    Sixth choice is value 8: Other

FY2025: Third panel of table 1 0 D
  Fourth character (Body Part) is value 1: Products of Conception, Retained
  Fifth character (Approach) is value 0: Open
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fourth panel of table 1 0 D
  Fourth character (Body Part) is value 1: Products of Conception, Retained
  Fifth character (Approach) has 2 choices.
    First choice is value 7: Via Natural or Artificial Opening
    Second choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) has 2 choices.
    First choice is value 9: Manual
    Second choice is value Z: No Qualifier

No change: Fifth panel of table 1 0 D
  Fourth character (Body Part) is value 2: Products of Conception, Ectopic
  Fifth character (Approach) has 4 choices.
    First choice is value 0: Open
    Second choice is value 4: Percutaneous Endoscopic
    Third choice is value 7: Via Natural or Artificial Opening
    Fourth choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device) is value Z: No Device
  Seventh character (Qualifier) is value Z: No Qualifier

No change: table 3 E 0
  First character (Section) is value 3: Administration
  Second character (Body System) is value E: Physiological Systems and Anatomical Regions
  Third character (Operation) is value 0: Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

No change: First panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Second panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Third panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value B: Anesthetic Agent
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value M: Pigment
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 0: Skin and Mucous Membranes
  Fifth character (Approach) is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) is value A: Anti-Infective Envelope

No change: Sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 3 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective
    Third choice is value A: Anti-Infective Envelope

No change: Eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 4: Serum, Toxoid and Vaccine
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Influenza Vaccine
    Second choice is value Z: No Qualifier

No change: Tenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eleventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 2 choices.
    First choice is value G: Insulin
    Second choice is value J: Other Hormone

No change: Twelfth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Thirteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Fourteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 4: Serum, Toxoid and Vaccine
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Influenza Vaccine
    Second choice is value Z: No Qualifier

No change: Sixteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Seventeenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Eighteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Nineteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Twentieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Twenty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Twenty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Twenty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Twenty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Twenty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Twenty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Twenty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Twenty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Twenty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 4 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption
    Third choice is value Q: Glucarpidase
    Fourth choice is value R: Other Therapeutic Monoclonal Antibody

No change: Thirtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Thirty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Thirty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Thirty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Thirty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Thirty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Thirty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Thirty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Thirty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Thirty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Fortieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Forty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Forty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Forty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Forty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 4 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption
    Third choice is value Q: Glucarpidase
    Fourth choice is value R: Other Therapeutic Monoclonal Antibody

No change: Forty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Forty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Forty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 5: Other Antineoplastic
    Fourth choice is value M: Monoclonal Antibody
    Fifth choice is value P: Clofarabine

No change: Forty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Forty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Fiftieth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 12 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value F: Intracirculatory Anesthetic
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value P: Platelet Inhibitor
    Tenth choice is value R: Antiarrhythmic
    Eleventh choice is value T: Destructive Agent
    Twelfth choice is value X: Vasopressor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value C: Other Substance
    Second choice is value N: Blood Brain Barrier Disruption

No change: Fifty-second panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value V: Hormone
  Seventh character (Qualifier) has 3 choices.
    First choice is value G: Insulin
    Second choice is value H: Human B-type Natriuretic Peptide
    Third choice is value J: Other Hormone

No change: Fifty-third panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 5: Peripheral Artery
    Second choice is value 6: Central Artery
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value W: Immunotherapeutic
  Seventh character (Qualifier) has 2 choices.
    First choice is value K: Immunostimulator
    Second choice is value L: Immunosuppressive

No change: Fifty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 6: Recombinant Human-activated Protein C
    Second choice is value 7: Other Thrombolytic

No change: Fifty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Fifty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 2 choices.
    First choice is value K: Other Diagnostic Substance
    Second choice is value P: Platelet Inhibitor
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Fifty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value 7: Coronary Artery
    Second choice is value 8: Heart
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Fifty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Fifty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Sixtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value B: Anesthetic Agent
    Fourth choice is value H: Radioactive Substance
    Fifth choice is value K: Other Diagnostic Substance
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Sixty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value 9: Nose
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value A: Bone Marrow
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: Sixty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value A: Bone Marrow
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Sixty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Sixty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 6 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value H: Radioactive Substance
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value N: Analgesics, Hypnotics, Sedatives
    Sixth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Sixty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value B: Ear
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Sixty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Sixty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Seventieth panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 7 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value H: Radioactive Substance
    Fourth choice is value K: Other Diagnostic Substance
    Fifth choice is value M: Pigment
    Sixth choice is value N: Analgesics, Hypnotics, Sedatives
    Seventh choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Seventy-first panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Seventy-second panel of table 3 E 0
  Fourth character (Body System / Region) is value C: Eye
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Seventy-third panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Seventy-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Seventy-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) has 10 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 4: Serum, Toxoid and Vaccine
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value R: Antiarrhythmic
    Tenth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Seventy-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value D: Mouth and Pharynx
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value X: External
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Seventy-seventh panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Seventy-eighth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Seventy-ninth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Eightieth panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Eighty-second panel of table 3 E 0
  Fourth character (Body System / Region) has 5 choices.
    First choice is value E: Products of Conception
    Second choice is value G: Upper GI
    Third choice is value H: Lower GI
    Fourth choice is value K: Genitourinary Tract
    Fifth choice is value N: Male Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Eighty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Eighty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Eighty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) has 2 choices.
    First choice is value D: Nitric Oxide
    Second choice is value F: Other Gas

No change: Eighty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value F: Respiratory Tract
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Eighty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Ninetieth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: Ninety-first panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninety-second panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Ninety-third panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: Ninety-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) has 3 choices.
    First choice is value 3: Percutaneous
    Second choice is value 7: Via Natural or Artificial Opening
    Third choice is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value U: Pancreatic Islet Cells
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: Ninety-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value J: Biliary and Pancreatic Tract
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: Ninety-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: Ninety-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: Ninety-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 1: Thrombolytic
  Seventh character (Qualifier) is value 7: Other Thrombolytic

No change: Ninety-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundredth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred First panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Second panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Third panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value L: Pleural Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 4 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody
    Fourth choice is value Y: Hyperthermic

No change: One hundred Ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Tenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eleventh panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Twelfth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Thirteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fourteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Sixteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value M: Peritoneal Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Seventeenth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eighteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Nineteenth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Twentieth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 11 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 5: Adhesion Barrier
    Third choice is value 6: Nutritional Substance
    Fourth choice is value 7: Electrolytic and Water Balance Substance
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value L: Sperm
    Ninth choice is value N: Analgesics, Hypnotics, Sedatives
    Tenth choice is value T: Destructive Agent
    Eleventh choice is value V: Hormone
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twenty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Twenty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value Q: Fertilized Ovum
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Twenty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Twenty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value 5: Adhesion Barrier
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twenty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Twenty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Twenty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Twenty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) has 10 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value L: Sperm
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
    Tenth choice is value V: Hormone
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Twenty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Thirtieth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value Q: Fertilized Ovum
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Thirty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Thirty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Thirty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Thirty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Thirty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Thirty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value P: Female Reproductive
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Thirty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Thirty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Thirty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value A: Stem Cells, Embryonic
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fortieth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Forty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Forty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Forty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Forty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Forty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value A: Stem Cells, Embryonic
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Forty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Forty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 4: Liquid Brachytherapy Radioisotope
    Fourth choice is value 5: Other Antineoplastic
    Fifth choice is value M: Monoclonal Antibody

No change: One hundred Forty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Forty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 9 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value A: Stem Cells, Embryonic
    Fifth choice is value B: Anesthetic Agent
    Sixth choice is value H: Radioactive Substance
    Seventh choice is value K: Other Diagnostic Substance
    Eighth choice is value N: Analgesics, Hypnotics, Sedatives
    Ninth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fiftieth panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value E: Stem Cells, Somatic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 0: Autologous
    Second choice is value 1: Nonautologous

No change: One hundred Fifty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fifty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value R: Spinal Canal
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fifty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 5 choices.
    First choice is value 2: High-dose Interleukin-2
    Second choice is value 3: Low-dose Interleukin-2
    Third choice is value 4: Liquid Brachytherapy Radioisotope
    Fourth choice is value 5: Other Antineoplastic
    Fifth choice is value M: Monoclonal Antibody

No change: One hundred Fifty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Fifty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Fifty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Fifty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Fifty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value S: Epidural Space
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Sixtieth panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value T: Peripheral Nerves and Plexi
    Second choice is value X: Cranial Nerves
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 3 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value B: Anesthetic Agent
    Third choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Sixty-first panel of table 3 E 0
  Fourth character (Body System / Region) has 2 choices.
    First choice is value T: Peripheral Nerves and Plexi
    Second choice is value X: Cranial Nerves
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Sixty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

FY2025: One hundred Sixty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Sixty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Sixty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Sixty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Sixty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Sixty-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Sixty-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value U: Joints
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Seventieth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 0: Open
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Seventy-first panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: One hundred Seventy-second panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Seventy-third panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Seventy-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) has 2 choices.
    First choice is value B: Recombinant Bone Morphogenetic Protein
    Second choice is value C: Other Substance

No change: One hundred Seventy-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value V: Bones
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Seventy-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 2 choices.
    First choice is value 5: Other Antineoplastic
    Second choice is value M: Monoclonal Antibody

No change: One hundred Seventy-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Seventy-eighth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Seventy-ninth panel of table 3 E 0
  Fourth character (Body System / Region) is value W: Lymphatics
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eightieth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Eighty-first panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value 2: Anti-infective
  Seventh character (Qualifier) has 2 choices.
    First choice is value 8: Oxazolidinones
    Second choice is value 9: Other Anti-infective

No change: One hundred Eighty-second panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) has 8 choices.
    First choice is value 3: Anti-inflammatory
    Second choice is value 6: Nutritional Substance
    Third choice is value 7: Electrolytic and Water Balance Substance
    Fourth choice is value B: Anesthetic Agent
    Fifth choice is value H: Radioactive Substance
    Sixth choice is value K: Other Diagnostic Substance
    Seventh choice is value N: Analgesics, Hypnotics, Sedatives
    Eighth choice is value T: Destructive Agent
  Seventh character (Qualifier) is value Z: No Qualifier

No change: One hundred Eighty-third panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eighty-fourth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

No change: One hundred Eighty-fifth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 4: Percutaneous Endoscopic
  Sixth character (Substance) is value G: Other Therapeutic Substance
  Seventh character (Qualifier) is value C: Other Substance

No change: One hundred Eighty-sixth panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value 0: Antineoplastic
  Seventh character (Qualifier) has 3 choices.
    First choice is value 4: Liquid Brachytherapy Radioisotope
    Second choice is value 5: Other Antineoplastic
    Third choice is value M: Monoclonal Antibody

No change: One hundred Eighty-seventh panel of table 3 E 0
  Fourth character (Body System / Region) is value Y: Pericardial Cavity
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Substance) is value S: Gas
  Seventh character (Qualifier) is value F: Other Gas

FY2025: table D 2 2
  First character (Section) is value D: Radiation Therapy
  Second character (Body System) is value 2: Heart and Great Vessels
  Third character (Modality) is value 2: Stereotactic Radiosurgery

FY2025: First panel of table D 2 2
  Fourth character (Treatment Site) is value 8: Conduction Mechanism
  Fifth character (Modality Qualifier) is value D: Stereotactic Other Photon Radiosurgery
  Sixth character (Isotope) is value Z: None
  Seventh character (Qualifier) is value Z: None

No change: table X 2 K
  First character (Section) is value X: New Technology
  Second character (Body System) is value 2: Cardiovascular System
  Third character (Operation) is value K: Bypass: Altering the route of passage of the contents of a tubular body part

FY2025: First panel of table X 2 K
  Fourth character (Body Part) is value A: Atrium, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Conduit through Coronary Sinus to Right Atrium
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Second panel of table X 2 K
  Fourth character (Body Part) has 2 choices.
    First choice is value B: Radial Artery, Right
    Second choice is value C: Radial Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 1: Thermal Resistance Energy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Third panel of table X 2 K
  Fourth character (Body Part) has 2 choices.
    First choice is value H: Femoral Artery, Right
    Second choice is value J: Femoral Artery, Left
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value D: Conduit through Femoral Vein to Superficial Femoral Artery
    Second choice is value E: Conduit through Femoral Vein to Popliteal Artery
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: table X 2 U
  First character (Section) is value X: New Technology
  Second character (Body System) is value 2: Cardiovascular System
  Third character (Operation) is value U: Supplement: Putting in or on biological or synthetic material that physically reinforces and/or augments the function of a portion of a body part

No change: First panel of table X 2 U
  Fourth character (Body Part) is value 4: Coronary Artery/Arteries
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 7: Vein Graft Extraluminal Support Device(s)
  Seventh character (Qualifier) is value 9: New Technology Group 9

FY2025: Second panel of table X 2 U
  Fourth character (Body Part) is value 9: Atrium, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Y: Intraluminal Device, Heterotopic Bioprosthetic Valve(s)
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Third panel of table X 2 U
  Fourth character (Body Part) has 2 choices.
    First choice is value Q: Upper Extremity Vein, Right
    Second choice is value R: Upper Extremity Vein, Left
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value P: Synthetic Substitute, Extraluminal Support Device
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: table X N S
  First character (Section) is value X: New Technology
  Second character (Body System) is value N: Bones
  Third character (Operation) is value S: Reposition: Moving to its normal location, or other suitable location, all or a portion of a body part

No change: First panel of table X N S
  Fourth character (Body Part) is value 0: Lumbar Vertebra
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 3: Magnetically Controlled Growth Rod(s)
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Second panel of table X N S
  Fourth character (Body Part) is value 0: Lumbar Vertebra
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value C: Posterior (Dynamic) Distraction Device
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Third panel of table X N S
  Fourth character (Body Part) is value 0: Lumbar Vertebra
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 3: Magnetically Controlled Growth Rod(s)
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Fourth panel of table X N S
  Fourth character (Body Part) is value 0: Lumbar Vertebra
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Posterior (Dynamic) Distraction Device
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifth panel of table X N S
  Fourth character (Body Part) is value 3: Cervical Vertebra
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 3: Magnetically Controlled Growth Rod(s)
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Sixth panel of table X N S
  Fourth character (Body Part) is value 4: Thoracic Vertebra
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value 3: Magnetically Controlled Growth Rod(s)
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Seventh panel of table X N S
  Fourth character (Body Part) is value 4: Thoracic Vertebra
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value C: Posterior (Dynamic) Distraction Device
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2025: Eighth panel of table X N S
  Fourth character (Body Part) is value 4: Humeral Shaft, Right
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value G: Ring External Fixation Device with Automated Strut Adjustment
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Ninth panel of table X N S
  Fourth character (Body Part) is value 4: Thoracic Vertebra
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 3: Magnetically Controlled Growth Rod(s)
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Tenth panel of table X N S
  Fourth character (Body Part) is value 4: Thoracic Vertebra
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Posterior (Dynamic) Distraction Device
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2025: Eleventh panel of table X N S
  Fourth character (Body Part) is value 4: Humeral Shaft, Right
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Ring External Fixation Device with Automated Strut Adjustment
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2025: Twelfth panel of table X N S
  Fourth character (Body Part) has 13 choices.
    First choice is value 5: Humeral Shaft, Left
    Second choice is value 6: Radius, Right
    Third choice is value 7: Radius, Left
    Fourth choice is value 8: Ulna, Right
    Fifth choice is value 9: Ulna, Left
    Sixth choice is value A: Upper Femur, Right
    Seventh choice is value B: Upper Femur, Left
    Eighth choice is value C: Lower Femur, Right
    Ninth choice is value D: Lower Femur, Left
    Tenth choice is value E: Femoral Shaft, Right
    Eleventh choice is value F: Femoral Shaft, Left
    Twelfth choice is value G: Tibia, Right
    Thirteenth choice is value H: Tibia, Left
  Fifth character (Approach) has 2 choices.
    First choice is value 0: Open
    Second choice is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Ring External Fixation Device with Automated Strut Adjustment
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: table X W 0
  First character (Section) is value X: New Technology
  Second character (Body System) is value W: Anatomical Regions
  Third character (Operation) is value 0: Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

No change: First panel of table X W 0
  Fourth character (Body Part) is value 0: Skin
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 2: Anacaulase-bcdb
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Second panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 1: Daratumumab and Hyaluronidase-fihj
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Third panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 2: Talquetamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fourth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 4: Teclistamab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Fifth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Dasiglucagon
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Sixth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Satralizumab-mwge
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventh panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Eighth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value G: REGN-COV2 Monoclonal Antibody
    Second choice is value H: Other New Technology Monoclonal Antibody
    Third choice is value K: Leronlimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: Elranatamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Tenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value S: COVID-19 Vaccine Dose 1
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eleventh panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value S: Epcoritamab Monoclonal Antibody
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Twelfth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value T: COVID-19 Vaccine Dose 2
    Second choice is value U: COVID-19 Vaccine
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Thirteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value V: COVID-19 Vaccine Dose 3
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fourteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fifteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: COVID-19 Vaccine Booster
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Sixteenth panel of table X W 0
  Fourth character (Body Part) is value 1: Subcutaneous Tissue
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 2: Anacaulase-bcdb
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventeenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value D: Engineered Allogeneic Thymus Tissue
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighteenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value S: COVID-19 Vaccine Dose 1
    Second choice is value T: COVID-19 Vaccine Dose 2
    Third choice is value U: COVID-19 Vaccine
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Nineteenth panel of table X W 0
  Fourth character (Body Part) is value 2: Muscle
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 4 choices.
    First choice is value V: COVID-19 Vaccine Dose 3
    Second choice is value W: COVID-19 Vaccine Booster
    Third choice is value X: Tixagevimab and Cilgavimab Monoclonal Antibody
    Fourth choice is value Y: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twentieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Brexanolone
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Twenty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Spesolimab Monoclonal Antibody
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Twenty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 2: Nerinitide
    Second choice is value 3: Durvalumab Antineoplastic
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Twenty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Bentracimab, Ticagrelor Reversal Agent
    Second choice is value 4: Cefepime-taniborbactam Anti-infective
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Twenty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Narsoplimab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twenty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Mosunetuzumab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Twenty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Ceftobiprole Medocaril Anti-infective
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Twenty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Lefamulin Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Twenty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Terlipressin
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twenty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Afamitresgene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirtieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Coagulation Factor Xa, Inactivated
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Thirty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Trilaciclib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Thirty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Tabelecleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Lurbinectedin
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Thirty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Treosulfan
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Obecabtagene Autoleucel
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Thirty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Ceftolozane/Tazobactam Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Thirty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Inebilizumab-cdon
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Odronextamab Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Thirty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Cefiderocol Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fortieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Ciltacabtagene Autoleucel
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Forty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Cytarabine and Daunorubicin Liposome Antineoplastic
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Forty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Omadacycline Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Forty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Amivantamab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Forty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Orca-T Allogeneic T-cell Immunotherapy
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Forty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Eculizumab
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Forty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Forty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Zanidatamab Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Forty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value D: Atezolizumab Antineoplastic
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Forty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value D: Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Fiftieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Remdesivir Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fifty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Etesevimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fifty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Fifty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fifty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Bamlanivimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fifty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Fifty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Sarilumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Fifty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: REGN-COV2 Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Fifty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fifty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Tocilizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Sixtieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Sixty-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value H: Axicabtagene Ciloleucel Immunotherapy
    Second choice is value J: Tisagenlecleucel Immunotherapy
    Third choice is value K: Idecabtagene Vicleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Sixty-second panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Sulbactam-Durlobactam
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Sixty-third panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: CD24Fc Immunomodulator
  Seventh character (Qualifier) is value 6: New Technology Group 6

FY2025: Sixty-fourth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value L: Lifileucel Immunotherapy
    Second choice is value M: Brexucabtagene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2025: Sixty-fifth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value M: Emapalumab-lzsg Anti-IFNy Monoclonal Antibody
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2025: Sixty-sixth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Lisocabtagene Maraleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2025: Sixty-seventh panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Tarlatamab-dlle Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Sixty-eighth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value P: Glofitamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Sixty-ninth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Tagraxofusp-erzs Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Seventieth panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value Q: Posoleucel
    Second choice is value R: Rezafungin
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Seventy-first panel of table X W 0
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value S: Iobenguane I-131 Antineoplastic
    Second choice is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Seventy-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Brexanolone
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Seventy-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 0: Spesolimab Monoclonal Antibody
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventy-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 2: Nerinitide
    Second choice is value 3: Durvalumab Antineoplastic
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Seventy-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Bentracimab, Ticagrelor Reversal Agent
    Second choice is value 4: Cefepime-taniborbactam Anti-infective
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Seventy-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Narsoplimab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Seventy-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Mosunetuzumab Antineoplastic
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventy-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 5: Ceftobiprole Medocaril Anti-infective
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Seventy-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Lefamulin Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eightieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Terlipressin
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Eighty-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 6: Afamitresgene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighty-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Coagulation Factor Xa, Inactivated
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: Eighty-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Trilaciclib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Eighty-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Tabelecleucel Immunotherapy
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighty-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Lurbinectedin
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Eighty-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Treosulfan
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighty-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 8: Obecabtagene Autoleucel
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Eighty-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Ceftolozane/Tazobactam Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eighty-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Inebilizumab-cdon
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Ninetieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 9: Odronextamab Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Ninety-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Cefiderocol Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value A: Ciltacabtagene Autoleucel
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Ninety-third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Cytarabine and Daunorubicin Liposome Antineoplastic
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: Ninety-fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Omadacycline Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Amivantamab Monoclonal Antibody
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Ninety-sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value B: Orca-T Allogeneic T-cell Immunotherapy
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Ninety-seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Eculizumab
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Ninety-eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Ninety-ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value C: Zanidatamab Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundredth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value D: Atezolizumab Antineoplastic
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred First panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Remdesivir Anti-infective
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value E: Etesevimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Third panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 3: New Technology Group 3

No change: One hundred Fourth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Fifth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Bamlanivimab Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Sixth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value F: Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundred Seventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Sarilumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Eighth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: REGN-COV2 Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Ninth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value G: Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Tenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Tocilizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Eleventh panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Other New Technology Monoclonal Antibody
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twelfth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value H: Axicabtagene Ciloleucel Immunotherapy
    Second choice is value J: Tisagenlecleucel Immunotherapy
    Third choice is value K: Idecabtagene Vicleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Thirteenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value K: Sulbactam-Durlobactam
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Fourteenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value L: CD24Fc Immunomodulator
  Seventh character (Qualifier) is value 6: New Technology Group 6

FY2025: One hundred Fifteenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value L: Lifileucel Immunotherapy
    Second choice is value M: Brexucabtagene Autoleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2025: One hundred Sixteenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value M: Emapalumab-lzsg Anti-IFNy Monoclonal Antibody
  Seventh character (Qualifier) is value A: New Technology Group 10

FY2025: One hundred Seventeenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Lisocabtagene Maraleucel Immunotherapy
  Seventh character (Qualifier) is value 7: New Technology Group 7

FY2025: One hundred Eighteenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value N: Tarlatamab-dlle Antineoplastic
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundred Nineteenth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value P: Glofitamab Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Twentieth panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value Q: Tagraxofusp-erzs Antineoplastic
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Twenty-first panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value Q: Posoleucel
    Second choice is value R: Rezafungin
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Twenty-second panel of table X W 0
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value S: Iobenguane I-131 Antineoplastic
    Second choice is value W: Caplacizumab
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Twenty-third panel of table X W 0
  Fourth character (Body Part) is value 5: Peripheral Artery
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value T: Melphalan Hydrochloride Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Twenty-fourth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 3: Maribavir Anti-infective
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Twenty-fifth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 6: Lefamulin Anti-infective
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Twenty-sixth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 8: Uridine Triacetate
  Seventh character (Qualifier) is value 2: New Technology Group 2

No change: One hundred Twenty-seventh panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value F: Other New Technology Therapeutic Substance
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: One hundred Twenty-eighth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value J: Quizartinib Antineoplastic
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Twenty-ninth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Thirtieth panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Thirty-first panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value N: SER-109
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: One hundred Thirty-second panel of table X W 0
  Fourth character (Body Part) is value D: Mouth and Pharynx
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value R: Fostamatinib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Thirty-third panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Maribavir Anti-infective
    Second choice is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Thirty-fourth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Thirty-fifth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value R: Fostamatinib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Thirty-sixth panel of table X W 0
  Fourth character (Body Part) is value G: Upper GI
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value 8: Mineral-based Topical Hemostatic Agent
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Thirty-seventh panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 3: Maribavir Anti-infective
    Second choice is value K: Sabizabulin
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Thirty-eighth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value M: Baricitinib
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Thirty-ninth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value R: Fostamatinib
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Fortieth panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value X: Broad Consortium Microbiota-based Live Biotherapeutic Suspension
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: One hundred Forty-first panel of table X W 0
  Fourth character (Body Part) is value H: Lower GI
  Fifth character (Approach) is value 8: Via Natural or Artificial Opening Endoscopic
  Sixth character (Device / Substance / Technology) is value 8: Mineral-based Topical Hemostatic Agent
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Forty-second panel of table X W 0
  Fourth character (Body Part) has 4 choices.
    First choice is value J: Coronary Artery, One Artery
    Second choice is value K: Coronary Artery, Two Arteries
    Third choice is value L: Coronary Artery, Three Arteries
    Fourth choice is value M: Coronary Artery, Four or More Arteries
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 4 choices.
    First choice is value H: Paclitaxel-Coated Balloon Technology, One Balloon
    Second choice is value J: Paclitaxel-Coated Balloon Technology, Two Balloons
    Third choice is value K: Paclitaxel-Coated Balloon Technology, Three Balloons
    Fourth choice is value L: Paclitaxel-Coated Balloon Technology, Four or More Balloons
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundred Forty-third panel of table X W 0
  Fourth character (Body Part) is value Q: Cranial Cavity and Brain
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 1: Eladocagene exuparvovec
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: One hundred Forty-fourth panel of table X W 0
  Fourth character (Body Part) is value U: Joints
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value G: Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: One hundred Forty-fifth panel of table X W 0
  Fourth character (Body Part) is value V: Bones
  Fifth character (Approach) is value 0: Open
  Sixth character (Device / Substance / Technology) is value P: Antibiotic-eluting Bone Void Filler
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: One hundred Forty-sixth panel of table X W 0
  Fourth character (Body Part) is value V: Bones
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value W: AGN1 Bone Void Filler
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: table X W 1
  First character (Section) is value X: New Technology
  Second character (Body System) is value W: Anatomical Regions
  Third character (Operation) is value 1: Transfusion: Putting in blood or blood products

No change: First panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 2: Plasma, Convalescent (Nonautologous)
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Second panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Marnetegragene Autotemcel
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Third panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value B: Betibeglogene Autotemcel
    Second choice is value C: Omidubicel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Fourth panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value D: High-Dose Intravenous Immune Globulin
    Second choice is value E: Hyperimmune Globulin
  Seventh character (Qualifier) is value 7: New Technology Group 7

Revise from: Fifth panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value F: OTL-103
    Second choice is value G: OTL-200
  Seventh character (Qualifier) is value 8: New Technology Group 8

Revise to: Fifth panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value F: OTL-103
    Second choice is value G: Atidarsagene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Sixth panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Lovotibeglogene Autotemcel
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Seventh panel of table X W 1
  Fourth character (Body Part) is value 3: Peripheral Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value J: Exagamglogene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eighth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 2: Plasma, Convalescent (Nonautologous)
  Seventh character (Qualifier) is value 5: New Technology Group 5

No change: Ninth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value 7: Marnetegragene Autotemcel
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Tenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value B: Betibeglogene Autotemcel
    Second choice is value C: Omidubicel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Eleventh panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value D: High-Dose Intravenous Immune Globulin
    Second choice is value E: Hyperimmune Globulin
  Seventh character (Qualifier) is value 7: New Technology Group 7

Revise from: Twelfth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value F: OTL-103
    Second choice is value G: OTL-200
  Seventh character (Qualifier) is value 8: New Technology Group 8

Revise to: Twelfth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value F: OTL-103
    Second choice is value G: Atidarsagene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Thirteenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value H: Lovotibeglogene Autotemcel
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fourteenth panel of table X W 1
  Fourth character (Body Part) is value 4: Central Vein
  Fifth character (Approach) is value 3: Percutaneous
  Sixth character (Device / Substance / Technology) is value J: Exagamglogene Autotemcel
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: table X X E
  First character (Section) is value X: New Technology
  Second character (Body System) is value X: Physiological Systems
  Third character (Operation) is value E: Measurement: Determining the level of a physiological or physical function at a point in time

No change: First panel of table X X E
  Fourth character (Body Part) is value 0: Central Nervous
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 0: Intracranial Vascular Activity, Computer-aided Assessment
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Second panel of table X X E
  Fourth character (Body Part) is value 0: Central Nervous
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 1: Intracranial Cerebrospinal Fluid Flow, Computer-aided Triage and Notification
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Third panel of table X X E
  Fourth character (Body Part) is value 0: Central Nervous
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 4: Brain Electrical Activity, Computer-aided Semiologic Analysis
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Fourth panel of table X X E
  Fourth character (Body Part) is value 2: Cardiac
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 1: Output, Computer-aided Assessment
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Fifth panel of table X X E
  Fourth character (Body Part) is value 3: Arterial
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 2: Pulmonary Artery Flow, Computer-aided Triage and Notification
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Sixth panel of table X X E
  Fourth character (Body Part) is value 3: Arterial
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 5: Coronary Artery Flow, Quantitative Flow Ratio Analysis
    Second choice is value 6: Coronary Artery Flow, Computer-aided Valve Modeling and Notification
  Seventh character (Qualifier) is value 8: New Technology Group 8

No change: Seventh panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 2: Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Eighth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value 3: Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction
  Seventh character (Qualifier) is value 8: New Technology Group 8

FY2025: Ninth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 2 choices.
    First choice is value 4: Infection, Positive Blood Culture Small Molecule Sensor Array Technology
    Second choice is value 5: Immune Response, Whole Blood Cellular Assessment via Microfluidic Deformability
  Seventh character (Qualifier) is value A: New Technology Group 10

No change: Tenth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value N: Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility
  Seventh character (Qualifier) is value 6: New Technology Group 6

No change: Eleventh panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) has 3 choices.
    First choice is value R: Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure
    Second choice is value T: Intracranial Arterial Flow, Whole Blood mRNA
    Third choice is value V: Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Twelfth panel of table X X E
  Fourth character (Body Part) is value 5: Circulatory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value Y: Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology
  Seventh character (Qualifier) is value 9: New Technology Group 9

No change: Thirteenth panel of table X X E
  Fourth character (Body Part) is value 9: Nose
  Fifth character (Approach) is value 7: Via Natural or Artificial Opening
  Sixth character (Device / Substance / Technology) is value U: Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction
  Seventh character (Qualifier) is value 7: New Technology Group 7

No change: Fourteenth panel of table X X E
  Fourth character (Body Part) is value B: Respiratory
  Fifth character (Approach) is value X: External
  Sixth character (Device / Substance / Technology) is value Q: Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection
  Seventh character (Qualifier) is value 6: New Technology Group 6
